Compare Johnson & Johnson (JNJ) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Impinj Inc — how do they compare? Johnson & Johnson trades at $248.08 (market cap $598.96B), while Impinj Inc trades at $140.51 (market cap $4.19B). The key difference: Johnson & Johnson is far larger — about 142.9× Impinj Inc's market cap, and Johnson & Johnson pays a 2.15% dividend while Impinj Inc pays none. Which is the better fit depends on your goals.
| JNJ | PI | |
|---|---|---|
Market Cap | $598.96B | $4.19B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $241.91 |
52-Week Low | $164.36 | $91.34 |
Enterprise Value | $631.90B | $4.33B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Impinj (PI) trades at $137.72, down 0.33% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The company reported Q1 2026 EPS of $0.14, exceeding expectations, but maintains negative net income margins and high valuation multiples. Recent insider sales and mixed news flow highlight investor caution amid specialized RFID market positioning.
PI offers growth potential in RFID technology with strong analyst buy ratings (72.7% consensus) and a $167.50 price target, but faces significant risks from profitability challenges, high debt-to-asset ratio (51.52% in 2025), and competitive pressures. The stock's outlook hinges on execution improvement and market expansion to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
